[Clinical effects of allylestrenol on benign prostatic hypertrophy by double-blind method]. 1986

K Shida, and T Koyanagi, and K Kawakura, and T Nishida, and Y Kumamoto, and S Orikasa, and S Sato, and M Takeda, and H Yamanaka, and J Shimazaki

A double blind comparative clinical trial was performed with allylestrenol (AE) and chlormadinone acetate (CMA) to investigate the clinical efficacy of AE on prostatic hypertrophy. Both drugs were administered orally for 12-16 weeks in a daily dose of 50 mg. With both drugs marked improvement of disorders of micturition and a slight decrease in the size of the hypertrophied prostatic node were observed. No significant difference was observed between the two drugs in the overall efficacy of the treatments. Significant improvement of practically all parameters used for evaluation of results was observed with both drugs following treatment. Ultrasonotomographic examination revealed diminution of the size of the prostatic node and x-ray examination of the ureter showed improvement in elevation of the fundus of the bladder. These improvements were better after CMA treatment than after AE treatment. With all other parameters used no significant difference was observed between the two drugs. Mild adverse effects such as loss of sexual desire and potency were observed in a few cases. The incidence of side-effects was lower following AE treatment, and the incidence of loss of sexual desire and potency was significantly lower after AE than after CMA. Taking into consideration efficacy and safety of the treatments, no significant difference was observed in usefulness between the two drugs, and we were able to confirm the usefulness of AE for the conservative treatment of prostatic hypertrophy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D002715 Chlormadinone Acetate An orally active synthetic progestational hormone used often in combinations as an oral contraceptive (CONTRACEPTIVES, ORAL). Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro-,Chlormadinon Acetate,Chlormadinone,Chlormadinone Acetate, (9 beta,10 alpha)-Isomer,Neo-Eunomin,Neo Eunomin,NeoEunomin
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004963 Estrenes Unsaturated derivatives of the ESTRANES with methyl groups at carbon-13, with no carbon at carbon-10, and with no more than one carbon at carbon-17. They must contain one or more double bonds. 19-Norandrostenes,19 Norandrostenes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

K Shida, and T Koyanagi, and K Kawakura, and T Nishida, and Y Kumamoto, and S Orikasa, and S Sato, and M Takeda, and H Yamanaka, and J Shimazaki
March 1986, Hinyokika kiyo. Acta urologica Japonica,
K Shida, and T Koyanagi, and K Kawakura, and T Nishida, and Y Kumamoto, and S Orikasa, and S Sato, and M Takeda, and H Yamanaka, and J Shimazaki
March 1986, Hinyokika kiyo. Acta urologica Japonica,
K Shida, and T Koyanagi, and K Kawakura, and T Nishida, and Y Kumamoto, and S Orikasa, and S Sato, and M Takeda, and H Yamanaka, and J Shimazaki
August 1992, Hinyokika kiyo. Acta urologica Japonica,
K Shida, and T Koyanagi, and K Kawakura, and T Nishida, and Y Kumamoto, and S Orikasa, and S Sato, and M Takeda, and H Yamanaka, and J Shimazaki
July 1971, The British journal of surgery,
K Shida, and T Koyanagi, and K Kawakura, and T Nishida, and Y Kumamoto, and S Orikasa, and S Sato, and M Takeda, and H Yamanaka, and J Shimazaki
July 1993, Hinyokika kiyo. Acta urologica Japonica,
K Shida, and T Koyanagi, and K Kawakura, and T Nishida, and Y Kumamoto, and S Orikasa, and S Sato, and M Takeda, and H Yamanaka, and J Shimazaki
January 1993, Urologia internationalis,
K Shida, and T Koyanagi, and K Kawakura, and T Nishida, and Y Kumamoto, and S Orikasa, and S Sato, and M Takeda, and H Yamanaka, and J Shimazaki
September 1998, International journal of urology : official journal of the Japanese Urological Association,
K Shida, and T Koyanagi, and K Kawakura, and T Nishida, and Y Kumamoto, and S Orikasa, and S Sato, and M Takeda, and H Yamanaka, and J Shimazaki
February 1977, British journal of urology,
K Shida, and T Koyanagi, and K Kawakura, and T Nishida, and Y Kumamoto, and S Orikasa, and S Sato, and M Takeda, and H Yamanaka, and J Shimazaki
April 1990, Hinyokika kiyo. Acta urologica Japonica,
K Shida, and T Koyanagi, and K Kawakura, and T Nishida, and Y Kumamoto, and S Orikasa, and S Sato, and M Takeda, and H Yamanaka, and J Shimazaki
October 1979, Horumon to rinsho. Clinical endocrinology,
Copied contents to your clipboard!